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LZ-101, a novel derivative of danofloxacin,
induces mitochondrial apoptosis by
stabilizing FOXO3a via blocking autophagy
flux in NSCLC cells
Yongjian Guo1, Yue Zhao2, Yuxin Zhou2, Xiaoqing Tang1, Zhiyu Li3 and Xiaotang Wang1
Abstract
Non-small-cell lung carcinoma (NSCLC) continues to be a vital disease worldwide for its high incidence and
consequent mortality rate. In this study, we investigated the anti-cancer effect of LZ-101, a new derivative of
danofloxacin, against non-small-cell lung cancer and the underlying mechanisms. In vitro, LZ-101 inhibited the viability
of human non-small cell lung cancer cell lines. We demonstrated that LZ-101 induced mitochondrial-mediated
apoptosis by increasing Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (ΔΨm), release of cytochrome c (Cyt
c) and apoptosis-inducing factor (AIF) in A549 cells. Further research illuminated that LZ-101 induced apoptosis was
related to the activation of FOXO3a/Bim pathway. Moreover, we found that LZ-101 increased the stability of FOXO3a
by blocking autophagy-dependent FOXO3a degradation. However, inhibition of autophagosome formation abolished
FOXO3a stabilization and apoptosis induced by LZ-101. In vivo, LZ-101 exerted a remarkable anti-tumor activity with
high safety in xenograft model inoculated A549 tumor through the same mechanism as in our in vitro study. In
conclusion, our findings indicated that LZ-101 induces mitochondrial apoptosis and stabilizes FOXO3a by blocking
autophagy flux.
Introduction
Lung cancer is a leading cause of cancer-related mor-
tality in a global perspective, of which non-small-cell lung
carcinoma (NSCLC) has the highest risk of causing lung
cancer-related deaths. Almost 80% of lung cancer-related
deaths occur in patients with non-small-cell lung can-
cer1,2. Despite recent advances in therapeutic regimen, the
curative effect is not so inspiring because of the poor
outcome3. Consequently, it is indispensable to develop
more effective therapies against lung cancer.
There are two major apoptosis pathways, the extrinsic
and intrinsic (mitochondria-associated) pathways, in
cytoplasm. Intrinsic apoptosis could be regulated via
mitochondrial pathway characterized by the release of
cytochrome c (Cyt c) and activation of caspase4. The Bcl-2
family proteins, anti-apoptotic proteins (such as Bcl-2 and
Bcl-xL), pro-apoptotic proteins (such as Bax and Bak),
and Bcl-2 homology 3-only (BH3-only) proteins (such as
Bim, Bad, and Puma), play a crucial role in intrinsic
apoptotic process. The apoptotic stimuli activate specific
BH3-only proteins to engage anti-apoptotic proteins and
release downstream pro-apoptotic proteins, leading to
increased mitochondrial outer membrane permeability
and eventually cell death induced by triggering caspase
cascade5. Subsequently, cytochrome c is released from
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mitochondria into cytoplasm which can trigger the cas-
pase cascade, leading to cell death. Bim acts as direct
activators of Bax and Bak by interacting with them. Bim is
also involved in p53-dependent and p53-independent
apoptosis6. Recent studies have implicated that Bim may
serve as a potential target for anti-cancer chemother-
apeutics since it plays an important role in apoptosis7,8.
The FOXO subfamily of transcription factors is evolu-
tionarily conserved, including FOXO1, FOXO3a, FOXO4,
and FOXO69. FOXO proteins can regulate multiple target
genes involved in tumor suppression, such as Bim, FasL,
p27kip1, cyclin D and GADD4510–13. FOXO3a, the most
important transcription factor in FOXO family, was
phosphorylated by Akt at Thr32, Ser253, and Ser315,
leading to FOXO3a translocate from nucleus to cytoplasm
and is consequently degraded by proteasome14. The
proteasome inhibitor MG132 increases the stability of
FOXO3a and induces apoptosis in thyroid cancer cell15.
In addition, studies have reported that FOXO3a is a
substrate for autophagy16. This suggests that FOXO3a
degradation depends not only on the proteasome path-
way, but also on autophagy activation.
LZ-101 is a derivative of danofloxacin that has been
developed specifically for veterinary use17. Danofloxacin
has been widely used for the treatment for respiratory
disease and urinary tract infections in animals, such as
chicken and buffalo18,19. However, studies have shown
that danofloxacin induces apoptosis by inducing oxidative
stress in renal tubular cells, epithelial cell line (LLC-PK1).
This study showed that danofloxacin exhibited apoptosis-
inducing effects. While the effect of danofloxacin deriva-
tive LZ-101 on apoptosis is still unclear. This study
demonstrated that LZ-101 induced apoptosis in A549
human non-small-cell lung cancer cells and inhibited
tumor growth with low systemic toxicity in BALB/c mice
bearing A549 tumor through mitochondria-associated
pathway by stabilizing FOXO3a via blocking autophagy
flux. Our results showed that LZ-101 exhibits remarkable
anti-tumor activity and is promising to serve as an
effective candidate for the treatment of human non-small-
cell lung cancer.
Results
LZ-101 inhibited cell viability in human non-small-cell lung
cancer cells
The chemical structure of LZ-101 was shown in Fig. 1a.
To evaluate the inhibitory effect of LZ-101 on human
non-small-cell lung cancer cells including A549, H1299,
and H460 cells, we investigated its effect on cell viability at
different concentrations with varying lengths (12, 24, or
48 h) of treatment. The IC50 (the concentration of drug
inhibiting 50% of cells) values for A549 cells were 13.95 ±
2.24, 8.61 ± 0.75, and 4.28 ± 0.42 μM, respectively, after
12, 24, and 48 h treatment (Fig. 1b). Whereas, the IC50
values for H1299 were 44.47 ± 6.54, 18.47 ± 0.86, and
6.75 ± 0.58 μM, respectively, after 12, 24, and 48 h treat-
ment (Fig. 1c). In H460 cells, the IC50 values were 22.49 ±
4.52, 13.15 ± 1.02, and 6.80 ± 0.72 μM, respectively, after
12, 24, and 48 h treatment (Fig. 1d). As shown in Fig. 1e,
treatment with 5, 10, and 15 μM LZ-101 for 24 h sig-
nificantly inhibited the surviving of A549, H1299, and
H460 cells with A549 cells being the most sensitive to
LZ101. Therefore, A549 cell line was chosen for further
experiments with 5, 10, and 15 μM of LZ-101 treatment
for 24 h. To explore the mechanism of LZ-101 inhibiting
A549, H1299, and H460 cells survival, cells were also
treated with a pan-caspase inhibitor, Q-VD-OPh, during
LZ-101 treatment. Survival inhibition of LZ-101 was sig-
nificantly inhibited in A549, H1299, and H460 cells, when
caspase activity was inhibited by Q-VD-OPh (Fig. 1f). This
suggests that LZ-101 inhibited the survival of human non-
small-cell lung cancer cells by triggering apoptosis.
LZ-101 induced mitochondrial apoptosis in A549 cells
To detect the apoptosis induced by LZ-101 in A549
cells, DAPI staining assay and Annexin-V/PI staining
were used with rotenone as positive control. In DAPI
staining assay, control cells emitted blue fluorescence with
consistent nucleus intensity and showed typical homo-
geneous distribution of chromatin in nucleus. After
LZ-101 treatment, cells presented morphological features
of bright apoptotic bodies and nuclear condensation (Fig. 2a
arrows). These features appeared more frequently with
increasing concentrations of LZ-101. To further confirm
the apoptosis induced by LZ-101, Annexin-V/PI staining
assay was used. As shown in Fig. 2b, increased apoptotic
was detected after LZ-101 treatment for 24 h. The per-
centage of apoptotic cells increased from 6.07% ± 1.62% to
14.92% ± 4.32%, 22.07% ± 4.32%, and 43.62% ± 7.83%,
respectively. Furthermore, the apoptosis related proteins
such as Bcl-2, Bax, caspase-9 and PARP were investigated
by Western blots. After treatment with LZ-101 for 24 h,
the apoptotic protein Bax expression increased while the
anti-apoptotic protein Bcl-2 expression decreased in a
concentration-dependent manner (Fig. 2c). The ratio of
Bax/Bcl-2 is crucial for the activation of the mitochondrial
apoptotic pathway. The ratio of Bax/Bcl-2 was increased
by different concentrations of LZ-101 treatment. Besides,
Caspase-9 and PARP cleavage were activated significantly
after LZ-101 treatment (Fig. 2c). These data indicated that
LZ-101 induced apoptosis in A549 cells.
In order to elucidate the mechanism of LZ-101-induced
apoptosis in A549 cells, we investigated the effect of LZ-
101 on mitochondrial function. Changes in mitochondrial
functions are essential for mitochondrial apoptotic path-
way. In early apoptosis stage, the change of mitochondrial
membrane potential (ΔΨm) is a marker for mitochondrial
dysfunction. Accordingly, we used a fluorogenic probe JC-
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1 staining cells to detect the change of ΔΨm after LZ-101
treatment. Flow cytometric analysis revealed that A549
cells became more susceptible to mitochondrial mem-
brane depolarization after LZ-101 treatment (Fig. 2d). We
observed almost 50% decrease in ΔΨm with 15 μM LZ-
101, compared with the control group. Multidomain pro-
apoptotic proteins like Bax and Bak play pivotal roles in
the release of apoptogenic proteins, such as cytochrome c
and AIF, from the mitochondria into the cytosol in
response to apoptotic stimuli20. To study the involvement
of Bax in LZ-101-induced apoptosis, we used Bax shRNA
to diminish the expression of Bax (Fig. 2e). As shown in
Fig. 2f, cytochrome c and AIF were released from mito-
chondria upon LZ-101 treatment whereas their release
was almost completely blocked in Bax knockdown cells
and β-actin levels of all the fractions were similar. Taken
together, our findings suggested that LZ-101 induced
apoptosis was mediated by mitochondrial dysfunction in
A549 cells.
The up-regulation of FOXO3a expression was involved in
LZ-101 induced apoptosis of mitochondrial
When cells receive intrinsic apoptosis signals, the pro-
apoptotic BH3-only proteins, such as Bim, Bad, Noxa, and
Puma, will be activated. These proteins not only inhibit
the activity of anti-apoptotic protein (Bcl-2, Bcl-xL, and
Mcl-1), but also activate the pro-apoptotic protein (Bax
and Bak), which form an oligomer and subsequently
punch pores in the outer mitochondrial membrane,
eventually, leading to permeabilization of mitochondrial
outer membrane6. As mentioned before, although pro-
apoptotic BH3-only protein Bim plays a crucial role in
apoptosis, it could be regulated by FOXO3a at tran-
scriptional level. Therefore, we investigated the effect of
Fig. 1 LZ-101 inhibits the viability of human non-small-cell lung cancer cells. a LZ-101 molecular structure (C26H23FN6O, Molecular Weight:
454.19). Effect of LZ-101 on the viability of human non-small cell lung cancer cells. MTT assay was used to detect cell viability after treatment of
different concentrations of LZ-101 for 12 h, 24 h, and 48 h in A549 (b), H1299 (c) and H460 (d). e Cell viability was detected after treatment of 5, 10,
and 15 μM LZ-101 for 24 h in A549, H1299, and H460 cells. f Cell viability was detected after treatment of 20 μM Q-VD-OPh or 15 μM LZ-101 for 24 h in
A549, H1299, and H460 cells. Data are presented as mean ± SD. *P < 0.05, **P < 0.01 compared with DMSO group. ##P < 0.01
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LZ-101 on this signaling pathway. Western blots analysis
showed that Bim increased in A549 cells after LZ-101
treatment for 24 h (Fig. 3a). This result confirms that
FOXO3a regulated the transcription of Bim. Moreover,
we found that LZ-101 up-regulated FOXO3a protein
expression in A549 cells (Fig. 3a). The change of mRNA
level of Bim, tested by Real-time PCR, was consistent with
that of the protein levels (Fig. 3b). Furthermore, Lucifer-
ase reporter gene assay suggested that LZ-101 increased
transcriptional activity of FOXO3a in a concentration-
dependent manner (Fig. 3c). LZ-101 also promoted
FOXO3a to translocate into the nucleus (Fig. 3d).
Therefore, LZ-101 up-regulates the expression of
FOXO3a and promotes the transcription of Bim.
To further explore the mechanism of LZ-101-induced
apoptosis and determine the roles of FOXO3a activation
in this process, we detected the influence of LZ-101 on
Bax and Bcl-2 expression after FOXO3a siRNA transfec-
tion. Western blot results showed that the protein level of
Bax and Bcl-2 were notably regulated by LZ-101. How-
ever, these effects of LZ-101 were obviously reversed by
the knockdown of FOXO3a (Fig. 3e). Remarkably, the
ratio of Bax/Bcl-2 increased by LZ-101 was also reversed.
Moreover, Flow cytometry analysis demonstrated that the
percentage of apoptotic cells in LZ-101 group transfected
with FOXO3a siRNA reduced from 50.47% ± 8.59% to
19.44% ± 3.63%, compared with LZ-101 group without
transfection with FOXO3a siRNA (Fig. 3f). The decrease
of mitochondrial potential was inhibited in LZ-101 group
transfected with FOXO3a siRNA compared with LZ-101
group (Fig. 3g). In conclusion, the up-regulation of
FOXO3a expression was involved in the induction of
mitochondrial apoptosis by LZ-101.
LZ-101 increased the stability of FOXO3a in a proteasome-
independent manner
To further investigate the molecular mechanism by
which LZ-101 up-regulates FOXO3a expression, de novo
protein synthesis inhibitor cycloheximide (CHX) and
proteasome inhibitor MG132 were used, respectively.
After treatment of CHX, FOXO3a was more stable in
A549 cells treated by LZ-101 compared with A549 cells
treated by DMSO (Fig. 4a), indicating that LZ-101 inter-
fered with FOXO3a degradation. In support of this
observation, when MG132 (20 μM) was added to A549
cells, increased FOXO3a levels were observed, whereas
LZ-101 unexpectedly further increased FOXO3a levels in
A549 cells treated with MG132 (Fig. 4b). Further detec-
tion of apoptosis levels showed that LZ-101 significantly
increased apoptosis induced by MG132 (Fig. 4c). These
results suggested that LZ-101 interfered with FOXO3a
degradation in a proteasome-independent manner. In
addition to proteasome degradation of proteins in cells,
the autophagic lysosomal pathway may also be involved in
protein degradation. To confirm this hypothesis we
detected the co-localization of FOXO3a and LAMP1 in
A549 cells. As shown in Fig. 4d, LZ-101 indeed inhibited
the co-localization of FOXO3a and LAMP1. To further
confirm FOXO3a is degraded by the autophagic lysosomal
pathway, an autophagolysosome inhibitor, bafilomycin
A1, was used. After treatment with bafilomycin A1,
FOXO3a degradation was inhibited, combination of
bafilomycin A1 with LZ-101 could not further inhibit
FOXO3a degradation (Fig. 4e). These results suggested
that LZ-101 increased the stability of FOXO3a through
the autophagic lysosome pathway rather than the ubi-
quitin proteasome pathway.
LZ-101 blocked autophagy flux in A549 cells
In Fig. 4d, 100 nM rapamycin remarkably increased the
co-localization of FOXO3a and LAMP1 in A549 cellls.
This is consistent with the study that FOXO3a is an
autophagy substrate16. To further investigate the mole-
cular mechanism by which LZ-101 increased the stability
of FOXO3a, we investigated the effect of LZ-101 on
autophagy. LC3-I and LC3-II are both produced post-
translationally, but LC3-I is cytosolic and LC3-II, the
hallmarks of autophagy, is membrane bound and forms
the autophagosome21. Treatment with 15 μM LZ-101
increased GFP-LC3 puncta accumulation (Fig. 5a). Then,
we assessed LC3 in the cell lysates by immunoblot ana-
lysis. We found that LC-II protein levels gradually
increased following treatment with LZ-101 in A549 cells
(Fig. 5b), indicateing that LZ-101 increased autophago-
some formation in A549 cells. Since enhanced autopha-
gosome accumulation could be caused either by
promoted autophagosome formation or by suppressed
autophagosome degradation, we determined whether a
(see figure on previous page)
Fig. 2 LZ-101 induces mitochondrial apoptosis in A549 cells. A549 cells were exposed to LZ-101 (5, 10, and 15 μM) or Rotenone (5 μM) for 24 h.
a DAPI staining was used to detect the apoptosis. Scale bars, 50 µm. b Induction of apoptosis were measured by Annexin-V/PI double-staining assay
(left). Histograms shows the distribution of apoptotic cells for three independent experiments (mean ± SD) (right). c The levels of Bax, Bcl-2, caspase-9,
and PARP were assessed by western blot. Ratio of Bax/Bcl-2 expression using densitometric analysis. d The change of ΔΨm as detected by flow
cytometry using JC-1 staining. e Bax were detected by western blot after transfection of Bax shRNA into A549 cells. f The release of Cyt c and AIF from
mitochondria into cytoplasm was measured by Western blot assay. Data are presented as mean ± SD. *P < 0.05, **P < 0.01 compared with
DMSO group
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complete autophagic flux occurred after LZ-101 treat-
ment. As shown in Fig. 4b, the degradation of p62 was
significantly suppressed in A549 cells with LZ-101 treat-
ment. To further assess the status of autophagic flux, we
used the mCherry-GFP-LC3 construct. As the more stable
of mCherry in acidic conditions compared with GFP,
autophagic flux can be determined by the appearance of
more GFP- mCherry+ (red) puncta. After treatment with
LZ-101, large-sized GFP+mCherry+ (yellow) puncta were
observed, while the yellow puncta did not change sig-
nificantly after bafilomycin A1 treatment (Fig. 5c, d).
These results indicated that LZ-101 blocked autophagy
flux in A549 cells by inhibiting autophagosome
degradation.
Inhibition of autophagosome formation abolished the
induction of apoptosis by LZ-101
To investigate the role of autophagy in the induction of
apoptosis by LZ-101, we blocked the formation of
autophagosomes with 3-MA. After treatment with 3-MA,
the effect of LZ-101 to stabilize FOXO3a abolished (Fig. 6a).
In addition, the effect of LZ-101 induced apoptosis
Fig. 3 LZ-101 induces mitochondrial apoptosis by up-regulating FOXO3a expression in A549 cells. a The levels of FOXO3a and Bim were
assessed by Western blot after 5, 10, and 15 μM LZ-101 treatment for 24 h. b Bim mRNA was measured by real-time PCR following treatment with 5,
10, and 15 μM LZ-101 for 24 h in A549 cells. β-actin was used as internal control. The relative levels were calculated to β-actin mRNA expression. c The
transcriptional activities of FOXO3a in A549 cells co-transfected with pGMFOXO-Lu and pRL-TK Renilla with LZ-101. Luciferase activity was
determined 24 h post-treatment by promega dual luciferase reporter assay system, normalized against values for the corresponding pRL-TK Renilla
activity. d Immunofluorescence staining of FOXO3a in A549 cells (treated with 15 μM LZ-101) was carried out to test the effect of LZ-101 on FOXO3a
protein nuclear translocation. Scale bars, 50 µm (left). Histograms shows the fold change of nuclear FOXO3a positive cells for three independent
experiments (mean ± SD) (right). FOXO3a siRNA was transfected into A549 cells. The cells were cultured in serum free medium overnight. After 8 h,
cells were treated with 15 μM LZ-101 for 24 h. e FOXO3a, Bim, Bax, and Bcl-2 were detected by Western blot (top). Ratio of Bax/Bcl-2 expression using
densitometric analysis (bottom). f Annexin-V/PI staining assay and g the change of ΔΨm were measured by flow cytometry. Data are presented as
mean ± SD. *P < 0.05, **P < 0.01 compared with DMSO group; #P < 0.05, ##P < 0.01 compared with LZ-101 treatment group
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was similarly abolished after treatment with 3-MA (Fig. 6b).
In the process of autophagy, ATG5 and ATG7 are
required for the formation of the autophagosome22. As
shown in Fig. 6c, we silenced the expression of ATG5 or
ATG7 through transfecting siRNA. The induction of
apoptosis was abolished after diminishing the expression
of ATG5 or ATG7 in LZ-101-treated A549 cells (Fig. 6d).
Thus, blocking the formation of autophagosome abol-
ished LZ-101 induced apoptosis of A549 cells.
LZ-101 exerted anti-tumor effect with low toxicity in A549
inoculated xenograft mice
The xenograft mice transplanted with A549 cells were
used to evaluate the anti-tumor effect of LZ-101 in vivo.
The tumor volume of mice with LZ-101 treatment was
smaller than that of mice in control group but larger than
that of mice in 5-fluorouracil-treated group at the same
measurement day (Fig. 7a). Moreover, the tumor weight
of LZ-101-treated mice was significantly smaller than that
of the control group (Fig. 7b). Accordingly, the inhibitory
rates of 5-fluorouracil, 10 mg/kg and 20mg/kg LZ-101
groups were 68.05%, 40.86%, and 55.62%, respectively
(Table 1). The TUNEL assay was performed to detect
apoptotic cells in tumor tissues. The results indicated that
DNA damage in tumor tissues was induced by LZ-101. In
addition, immunohistochemical analysis showed that Bcl-
2 expression were decreased while FOXO3a, Bim and Bax
expression were increased after LZ-101 treatment
(Fig. 7c). Furthermore, we monitored the toxicity of LZ-
101 during the entire in vivo experiment. LZ-101 treat-
ment (21 days) did not cause any physical abnormalities.
Hematological parameters showed that there were no
notable changes in the analyzed parameters in the
experimental animals, as listed in Table 2 with the stan-
dard ranges for mice. Besides, there was no significant
difference in the average body weight of LZ-101-treated
Fig. 4 LZ-101 stabilized FOXO3a proteins in a proteasome-independent manner in A549 cells. a Degradation dynamics of FOXO3a following a
time course CHX treatment in A549 cells treated with 15 μM LZ-101. b FOXO3a proteins were stabilized in the presence of MG132 (20 μM) in A549
cells treated with 15 μM LZ-101. c Annexin-V/PI staining assay measured by flow cytometry in the presence of MG132 (20 μM) in A549 cells treated
with 15 μM LZ-101. d Confocal microscopy of A549 cells treated with 15 μM LZ-101 or 100 nM rapamycin, immunostained for FOXO3a (green) and
LAMP-1 (red). Scale bars, 10 µm (top). Histograms shows the co-localized pixels of FOXO3a and LAMP1 per cell for three independent experiments
(mean ± SD) (bottom). e FOXO3a was detected by Western blot after 15 μM LZ-101 and 30 nM bafilomycin A1 treatment. Data are presented as
mean ± SD. *P < 0.05, **P < 0.01 compared with DMSO group; #P < 0.05, ##P < 0.01
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mice compared with that of the control mice (Fig. 7d).
H&E staining (Fig. 7e) showed no morphological changes
in the organs of mice with LZ-101 treatment. Taken
together, our results suggested that LZ-101 inhibited
tumor growth via FOXO3a activation in xenograft mice
bearing A549 tumor with low toxicity in vivo.
Discussion
LZ-101 is a derivative of danofloxacin, a fluor-
oquinolone antibiotic used in veterinary medicine. Pre-
vious studies indicated that high concentrations of
danofloxacin displayed cytotoxic effects involved apop-
tosis and/or necrosis. Danofloxacin also induced a
concentration-dependent increase in ROS production in
renal tubular cells epithelial cell line (LLC-PK1)23. In the
current study, we showed that LZ-101 had an effective
anti-tumor activity in vitro and in vivo by stabilizing
FOXO3a via blocking autophagy flux, eventually leading
to mitochondrial-mediated apoptosis.
Primarily, we found that LZ-101 could induce apoptosis
(Fig. 2a–c) and trigger caspase-9 activation and PARP
cleavage in A549 cells. Moreover, LZ-101 increased the
ratio of Bax/Bcl-2, the mitochondrial apoptotic indicator.
These results suggested that LZ-101 induced apoptosis
probably by activation of the mitochondrial apoptotic
pathway. Therefore, we further investigated the effect of
LZ-101 on mitochondrial apoptosis. The mitochondrial
apoptotic pathway is comprised of a series of continuous
processes. Our results showed that LZ-101 treatment
remarkably decreased mitochondrial membrane potential,
a marker for mitochondrial dysfunction in early apoptosis
stage. During apoptosis, cytochrome c and AIF retained
within mitochondria, are released from the inter-
membrane space into the cytosol. Afterwards, cytosolic
cytochrome c binds to Apaf-1 to form the apoptosome
which subsequently recruit procaspase-9 and facilitate its
activation. Ultimately, caspase-9 efficiently cleaves and
activates downstream caspase-3, leading to apoptosis24.
AIF translocates from the mitochondria to the nucleus
and causes chromatin condensation and DNA fragmen-
tation25. Our results suggested that LZ-101 induced the
release of cytochrome c and AIF from mitochondria into
the cytosol, which was dependent on Bax expression (Fig.
2e, f). Taken together, our study implied that LZ-101
induced apoptosis via mitochondrial apoptotic pathway.
The Bcl-2 family proteins are most important regulators
for apoptosis. This family consists of three subfamilies:
anti-apoptotic members, pro-apoptotic members, and
BH3-only members. Therein, the BH3-only members are
normally triggered to mitochondrial translocation in
Fig. 5 LZ-101 blocked autophagy flux in A549 cells. a Induction of GFP+ dots in A549 cells expressing GFP-LC3 treated with 15 μM LZ-101. Images
of individual cells and quantified of GFP-LC3+ cells. Scale bars, 10 µm. b p62 and LC3 were detected by western blot in A549 cells treated with 15 μM
LZ-101. c A549 cells expressing mCherry-GFP-LC3 were observed under a confocal microscopy after 15 μM LZ-101 and 30 nM bafilomycin A1
treatment. Representative images are shown. Scale bars, 10 µm. d The average numbers of yellow or red puncta were obtained from three countings.
Data are presented as mean ± SD. *P < 0.05, **P < 0.01 compared with DMSO group
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response to apoptotic stimuli26. Once translocated into
the mitochondria, they cause mitochondrial dysfunction
and release pro-apoptotic proteins by interacting with
other members of the Bcl-2 family27. Bim is a member of
BH3-only proteins that bind to dynein light chain LC8 of
microtubule complexes28. During apoptosis, Bim dis-
associates from the microtubule complex and translocates
to the mitochondria, leading to the release of cytochrome
c. When Bim gets into the mitochondria, the pro-
apoptotic members of the Bcl-2 family, such as Bax and
Bak, oligomerize into mitochondrial pores that are
required to induce the release of pro-apoptotic proteins29.
The members of the anti-apoptotic family, such as Bcl-2
and Bcl-xL, block the oligomerization of Bax and Bak but
do not affect the translocation of the BH3-only proteins to
the mitochondria30–32. In our study, LZ-101 promoted
Bax and Bim expression and inhibited Bcl-2 expression
(Figs. 2c and 3a). Transcriptional regulation of Bim may
be important for apoptosis. It has been documented that
Forkhead transcription factor FOXO3a, the most impor-
tant transcription factor in FOXO family, induced Bim
transcription33. Our study demonstrated that LZ-101
promoted FOXO3a expression, nuclear translocation and
transcriptional activity. Further studies showed that LZ-
101 inhibited FOXO3a degradation is independent of the
proteasome pathway (Fig. 4a–c). Since the ubiquitin
proteasome system and the autophagic lysosomal system
are involved in the degradation of FOXO3a, we next
studied the effect of LZ-101 on the autophagic lysosomal
pathway. As shown in Fig. 4d, LZ-101 inhibited the co-
localization of FOXO3a and LAMP-1. The combination
of bafilomycin A1 and LZ-101 failed to further inhibit the
degradation of FOXO3a (Fig. 4e). Further investigation of
the effect of LZ-101 on autophagy revealed that LZ-101
could increase the accumulation of autophagosomes and
block the autophagy flux (Fig. 5). Moreover, pharmaco-
logical or genetic inhibition of autophagosomes formation
abolished FOXO3a stabilization and apoptosis induced by
LZ-101 (Fig. 6). These results indicated that LZ-101
induced apoptosis by blocking autophagy-dependent
FOXO3a degradation. Consistent with our in vitro stu-
dies, LZ-101 significantly suppressed the tumor growth of
A549 inoculated xenograft mice with low toxicity in major
organs. Mechanistically, we found that LZ-101 could
induce apoptosis and regulate the expression of relevant
proteins in tumor tissues (Fig. 7).
In summary, LZ-101 displayed strong anti-tumor
activity both in vitro and in vivo based on the
Fig. 6 Apoptosis induced by LZ-101 was abolished after inhibition of autophagosome formation in A549 cells. a FOXO3a was detected by
western blot in the presence of 3-MA (4 mM) in A549 cells treated 15 μM LZ-101. b Annexin-V/PI staining assay by flow cytometry in the presence of
3-MA (4 mM) in A549 cells treated with 15 μM LZ-101. c ATG5 and ATG7 were detected by western blot after transfection of ATG5 or ATG7 siRNA into
A549 cells. d Annexin-V/PI staining assay by flow cytometry in A549 cells treated with 15 μM LZ-101 and transfected ATG5 or ATG7 siRNA. Data are
presented as mean ± SD. *P < 0.05, **P < 0.01 compared with DMSO group
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mitochondrial apoptosis induced by up-regulation of Bim
through stabilizing FOXO3a in autophagic lysosomal-
dependent manner (Fig. 8). However, how FOXO3a
escapes from autophagosomes to induce transcription
remains unknown. Studies have shown that inhibition of
autophagy in different means promoted the transcription
of FOXO3a16. It was suggested that inhibition of autop-
hagy induced FOXO3a activation was not a specific
function of LZ-101. Therefore, the relationship between
autophagy and FOXO3a activation needs further study
and is underway in our laboratories. In conclusion, this
Fig. 7 LZ-101 has a potential anti-tumor effect and low toxicity in vivo. a Tumor volumes of control, 5-fluorouracil, LZ-101 treatment groups
were measured and calculated every 3 days. b Weight of tumor in control, 5-fluorouracil, LZ-101 treatment groups. *P < 0.05, **P < 0.01 compared
with control group. c DNA damage and FOXO3a, Bim, Bcl-2, Bax expression detected by TUNEL assay and immunohistochemistry in tumor xenograft
tissues. Scale bars, 50 µm. d Nude mice weight was recorded every 3 days. e H&E stained main organs of mice from treated and control sets to
evaluate the toxicity of LZ-101. Scale bars, 50 µm
Table 1 Inhibitory activity of LZ-101 against A549
xenograft tumor
Groups Dose (mg/kg) Inhibitory rate (%)
5-Fluorouracil 30 68.05**
LZ-101 10 40.86**
20 55.62**
Each data point represents the mean SD of six mice
**P < 0.01 versus control group
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study indicated that LZ-101 could be a potential effective
agent with low toxicity for human non-small-cell lung
carcinoma.
Materials and methods
Reagents
LZ-101 was dissolved in DMSO to make a 100-mM stock
and stored at −20 °C until needed. The final concentration
of DMSO did not exceed 0.1% throughout the study. 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT), cycloheximide, 3-MA and diamidino-phenyl-indole
(DAPI) were from Sigma (St. Louis, USA). Rapamycin was
purchased form Cell Signaling Technology (Danvers, USA).
Bovine serum albumin (BSA) was purchased from Roche
(Mannheim, Germany).
Antibodies
Antibodies to Bax, Bcl-2, caspase-9, Cyt c, LAMP-1,
β-actin were from Santa Cruz Biotechnology (Dallas,
USA). Antibodies to FOXO3a was from Bioworld (St
Louis, USA). Antibodies to PARP, COX IV, AIF, Bim,
LC3, ATG5, ATG7 were from Cell Signaling Technology
(Danvers, USA) and antibody to SQSTM1/p62 were
obtained from Abcam (Cambridge, UK). IRDyeTM 800
conjugated secondary antibodies were from Rockland Inc.
(Philadelphia, USA) and diluted to the ratio of 1:15,000.
Cell culture
Human non-small cell lung cancer cell line H460 and
H1299 cells were cultured in RPMI-1640 medium (Gibco,
Waltham, USA) and A549 cells were cultured in F-12
medium (Gibco, Waltham, USA) supplemented with 10%
fetal bovine serum (Gibco, Waltham, USA), 100 U/ml
penicillin and 100 U/ml streptomycin, cells were cultured
Table 2 Hematology profile in non-tumor bearing
athymic nude mice administered with normal saline. Two
mice per group were used. Standard ranges were obtained
in house from 100 normal BALB/c mice of 8–12 weeks age
Hematological
parameters
Control 10mg/kg 20mg/kg Standard
White blood cells
(×103 μl)
4.71/4.42 4.90/4.95 5.87/5.74 4.5–9.1
Red blood cells
(×106/μl)
9.76/10.70 10.51/9.84 10.25/9.30 7.51–16.1
Hemoglobin (g/dL) 14.5/13.0 15.2/14.2 14.9/13.9 12.8–16.1
Hematocrit (%) 44.8/41.8 47.9/45.3 46.9/44.7 34–50
Lymphocytes (%) 67.2/78.8 50.4/61.4 55.4/63.1 49–82
Monocytes (%) 2.64/4.24 4.54/5.24 3.14/4.64 2–8
Eosinophils (%) 0.24/0.34 0.04/0.74 0.54/0.64 0–3
Basophils (%) 0.24/0.74 0.34/0.34 0.54/0.24 0–3
Platelet (×103μl) 507/410 560/483 526/744 115–1037
Mean corpuscular
volume (fL)
45.9/45.8 45.6/46.0 45.8/48.1 41–60
Mean corpuscular
hemoglobin (pg)
14.9/14.3 14.5/14.4 14.5/14.9 13–19
Fig. 8 The possible mechanism of LZ-101 induced apoptosis in A549 cells. LZ-101 stabilized FOXO3a to induce mitochondrial apoptosis of A549
cells by inhibiting the degradation of autophagosomes containing-FOXO3a
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in a humidified CO2 (5%) incubator (Thermo Forma,
Waltham, USA) at 37 °C.
MTT assay
Experiments were done in triplicate in a parallel manner
for each concentration of LZ-101 used and the results are
presented as mean ± SEM. Control cells were given culture
media containing 0.1% DMSO. After incubation for 24 or
48 h, 20 μL of 5mg/mL MTT was added to cells, and cells
were incubated at 37 °C for another 4 h. The absorbance
(A) was measured at 570 nm using an ELx800 automated
microplate reader (BioTek Instruments, Inc.). The inhibi-
tory ratio (%) was calculated using the following equation:
inhibitory ratio= (1 – average absorbance of treated
group/average absorbance of control group) × 100. IC50
was taken as the concentration that caused 50% inhibition
of cell viability and was calculated by the Logit method.
Annexin-V/PI staining
A549 cells were harvested, washed, and resuspended in
PBS after LZ-101 treatment, then stained with the
Annexin-V/PI Cell Apoptosis Detection Kit (KeyGen
Biotech, Nanjing, China) according to the manufacturer’s
instructions. Data acquisition and analysis were per-
formed with a Becton Dickinson FACS Calibur flow cyt-
ometer using Cell-Quest software (BD Biosciences,
Franklin Lakes, USA). The cells in early stages of apop-
tosis were Annexin-V positive and PI negative, whereas
the cells in the late stages of apoptosis were both
Annexin-V and PI positive.
Mitochondrial transmembrane potential (ΔΨm) assessment
The electrical potential difference across inner mem-
brane (ΔΨm) was monitored using the ΔΨm-specific
fluorescent probe JC-1 (Beyotime Institute of Bio-
technology, Shanghai, China)34. The ΔΨm-specific fluor-
escent probe JC-1 exists as a monomer with an emission
at 530 nm (green fluorescence) at low membrane poten-
tial but forms J-aggregates with an emission at 590 nm
(red fluorescence) at higher potentials. A549 cells were
treated with LZ-101 for 24 h. Cells were harvested and
incubated with JC-1 for 30 min at 37 °C in the dark, then
resuspended in washing buffer and relative fluorescence
intensities were monitored using flow cytometry (FACS-
Calibur, Becton Dickinson, USA) with settings of FL1
(green) at 530 nm and FL2 (red) 585 nm.
Preparation of whole cell lysates and cytosolic and nuclear
extracts
A549 cells were treated with LZ-101 at indicated con-
centrations for 24 h. The whole-cell lysates was prepared
as described35. Nuclear and cytosolic protein extracts
were prepared using a Nuclear/Cytosol Fractionation Kit
(BioVision, Mountain View, CA) according to the
manufacturer’s protocol. The cytosolic and nuclear frac-
tions were reserved for immunoblot analysis. Final
detection was performed with western blots.
Mitochondrial fractionation
Mitochondrial fractionation kit (KeyGen Biotech,
China) was used to get mitochondrial according to the
following protocol. The cells were treated with different
concentrations of LZ-101 for 24 h and 3.5 × 107 cells were
incubated with 1 mL ice-cold mitochondrial lyses buffer,
then suspended and ground the cells with tight pestle on
ice. The homogenate was subjected to centrifugation at
800 × g for 5 min at 4 °C to remove nuclei and unbroken
cells, and then added 0.5 mL supernatant to the 0.5 mL
Medium Buffer in the new 1.5 mL tube gently. After
centrifugation at 15,000 × g for 10 min at 4 °C, the
supernatant was carefully removed and collected as the
cytosolic fraction and the remaining mitochondrial pellet
was resuspended in the mitochondrial extraction buffer.
Western blot analysis
The whole cell lysates, cytosolic extracts, nuclear
extracts, and mitochondrial extracts were prepared as
described above. Western blot analysis was carried out as
described previously35. Protein samples were separated by
10% SDS-PAGE and transferred onto nitrocellulose
membranes. The membranes were incubated with 1%
BSA at 37℃ for 1 h and then indicated antibodies over-
night at 4℃, followed by IRDye800 conjugated secondary
antibody for 1 h at 37℃. Immunoreactive protein was
detected with an Odyssey Scanning System (LI-COR Inc.,
Lincoln, Nebraska).
Immunofluorescence microscopy
For confocal imaging of fixed cells, A549 cells were
used. After the appropriate treatment, cells were fixed
with 4% paraformaldehyde in PBS, permeabilized with
0.5% Triton X-100, and blocked with 3% BSA for 1 h.
Samples was incubated with primary antibodies (diluted
1:100) overnight at 4℃. After washed, Alexa Fluor 488
donkey anti-rabbit IgG, Alexa Fluor 594 donkey anti-
rabbit IgG were used as secondary antibodies (Invitrogen,
CA, USA). Samples were observed and captured with a
confocal laser scanning microscope (Olympus Corp.,
Tokyo, Japan).
Cell transfection
GFP-LC3, mCherry-GFP-LC3 plasmid (Addgene, MA,
USA), the siRNA targeting human FOXO3a, human
ATG5, human ATG7 or control siRNA and the shRNA
targeting human Bax or control shRNA with scrambled
sequence were transfected using Lipofectamine 2000™
reagent (Invitrogen, CA, USA) according to the manu-
facturer’s instructions.
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Luciferase assay
A549 cells were seeded in 6-well plate, cultured for 24 h,
and then transfected with 1 μg pGMFOXO-Lu (Geno-
meditech, Shanghai, China) and 0.05 μg pRL-TK Renilla
(Beyotime, Nantong, China) with 10 μl Lipofectamine
2000 and incubated for 24 h at 37℃ with LZ-101. Cells
were lysed with Promega passive lysis buffer and assayed
by using Promega dual luciferase (Firefly luciferase/
Renilla luciferase) kit. Luciferase intensity was detected
with a Luminoskan Ascent (Thermo Fisher Scientific Inc.
Finland).
Anti-tumor effects in nude mice
Male BALB/c nude mice, 35–40 days old and with
weight ranging from 18 to 22 g, were supplied by
Shanghai Laboratory Animal Limited Company. The mice
were maintained in a pathogen-free environment (23 ±
2℃ and 55 ± 5% humidity) on a 12 h light–12 h dark cycle
with food and water supplied ad libitum throughout the
experimental period. Mice were subcutaneously inocu-
lated with 1 × 106 A549 cells/nude mice. After
12–14 days, tumor sizes were determined using micro-
meter calipers, then nude mice with similar tumor volume
(eliminate mice with tumors that are too large or too
small) were randomly divided into four groups (6/group):
one saline tumor control group; (i.v.) 5-fluorouracil
30 mg/ml/2 days group; (i.v.) LZ-101 10mg/kg/2 days
group; (i.v.) LZ-101 20mg/ml/2 days group. At the end of
3 weeks, the mice were killed, and the tumor xenografts
were removed and measured. Tumor volume (TV) was
calculated using the following formula: TV (mm3)= d2 ×
D/2, where d and D are the shortest and the longest
diameters, respectively. This study was approved in SPF
Animal Laboratory of China Pharmaceutical University.
Relative tumor volume (RTV) was calculated according to
the equation: RTV=Vt/i0, where V0 is the tumor volume
at day 0 and Vt is the tumor volume at day t. And the
evaluation index for inhibition was of relative tumor
growth ratio T/C=TRTV/CRTV × 100%, where TRTV
and CRTV represented RTV of treated and control
groups, respectively.
TUNEL assay
Apoptosis induction in the tissue specimen was ana-
lyzed by TUNEL assay. It was performed as per instruc-
tions given in situ cell death kit. The slides were
photographed with a confocal laser scanning microscope
(Fluoview FV1000, Olympus, Tokyo, Japan).
Immunohistochemistry
The expression of FOXO3a, Bim, Bcl-2, Bax of the tis-
sues of control and LZ-101 (20 mg/kg) treated groups was
assessed by SP immunohistochemical method using a
rabbit-anti-human monoclonal antibody and an Ultra-
Sensitive SP kit (kit 9710 MAIXIN, Fuzhou, Fujian).
Tissue sections (4 mm thick) were placed onto treated
slides (Vectabond, Vector Laboratories, Burlingame, CA).
Sections were heat fixed, deparaffinized and rehydrated
through graded alcohols (100%, 95%, 85%, and 75%) to
distilled water. Tissue sections were boiled in citrate
buffer at high temperature for antigen retrieval, and
treated with 3% hydrogen peroxide to block endogenous
peroxidase activity. The slides were incubated with a
protein-blocking agent (kit 9710 MAIXIN, Fuzhou,
Fujian) prior to the application of the primary antibody,
and then incubated with the primary antibody at 4℃
overnight. The tissues were then incubated with the sec-
ondary biotinylated anti-species antibody and labeled
using a modification of the avidin–biotin complex
immunoperoxidase staining procedure according to the
UltraSensitive SP kit manual. Counterstaining was done
with Harris hematoxylin. All reagents were supplied by
MaixinBio Co. (Fuzhou, China).
Statistical analysis
All data in different experimental groups were expres-
sed as mean ± S.D. Data shown were obtained from at
least three independent experiments. Statistical analysis
was performed using an unpaired, two-tailed Student’s t-
test. All comparisons were made relative to untreated
controls and significance of difference is indicated as *p <
0.05 and **p < 0.01.
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